{
  "symbol": "CAH",
  "year": 2023,
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.1763,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.152
  },
  "top_positive": [
    {
      "sent": "The following tables summarize the outstanding interest rate swaps designated as fair value hedges at June 30: 2023 (in millions) Notional Amount Maturity\u00a0Date Pay-floating interest rate swaps $ 1,100 Jun 2027 - Sep 2030 2022 (in millions) Notional Amount Maturity\u00a0Date Pay-floating interest rate swaps $ 800 Jun 2027 - May 2029 The following table summarizes the gain/(loss) recognized in earnings for interest rate swaps designated as fair value hedges: (in millions) 2023 2022 2021 Pay-floating interest rate swaps (1) $ ( 50 ) $ ( 44 ) $ ( 8 ) Fixed-rate debt (1) 50 44 8 (1) Included in interest expense, net in the consolidated statements of earnings/(loss).",
      "score": 0.9796
    },
    {
      "sent": "Issuer Purchases of Equity Securities Period Total Number of Shares Purchased\u00a0(1) Average Price Paid\u00a0per Share Total Number of Shares Purchased as Part of Publicly Announced Programs\u00a0(2) Approximate Dollar Value of Shares That May Yet be Purchased Under the Programs\u00a0(3) (in millions) April 2023 234 $ 79.43 \u2014 $ 1,243 May 2023 137 83.79 \u2014 1,243 June 2023 4,588,337 87.18 4,588,208 4,343 Total 4,588,708 $ 87.18 4,588,208 $ 4,343 (1) Reflects 234, 137 and 129 common shares purchased in April, May and June 2023, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.",
      "score": 0.9578
    },
    {
      "sent": "Issuer Purchases of Equity Securities Period Total Number of Shares Purchased\u00a0(1) Average Price Paid\u00a0per Share Total Number of Shares Purchased as Part of Publicly Announced Programs\u00a0(2) Approximate Dollar Value of Shares That May Yet be Purchased Under the Programs\u00a0(3) (in millions) April 2023 234 $ 79.43 \u2014 $ 1,243 May 2023 137 83.79 \u2014 1,243 June 2023 4,588,337 87.18 4,588,208 4,343 Total 4,588,708 $ 87.18 4,588,208 $ 4,343 (1) Reflects 234, 137 and 129 common shares purchased in April, May and June 2023, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.",
      "score": 0.9578
    }
  ],
  "top_negative": [
    {
      "sent": "Our results of operations could be adversely affected if our or a service provider's business processes, information systems, critical facilities or distribution networks are disrupted (including disruption of access), are damaged or fail, whether due to physical disruptions, such as climate change-related weather events, including wildfires, hurricanes, extreme temperatures or other natural disasters, pandemics (as they were by the COVID-19 pandemic) or power outage, or due to cyber-security incidents, ransomware or other actions of third parties, including labor strikes or shortages, political unrest and terrorist attacks.",
      "score": -0.9753
    },
    {
      "sent": "For example, we are subject to a number of lawsuits and investigations related to the national health crisis involving the abuse of opioid pain medication as described above in the Risk Factor titled \" Opioid-related legal proceedings and the National Opioid Settlement Agreement we have entered into could have additional or unexpected negative effects on our results of operations or business\" and in Note 7 to the \"Notes to Consolidated Financial Statements.\" Additionally, some of the products that we distribute or manufacture have been and may in the future be alleged to cause personal injury, subjecting us to product liability claims.",
      "score": -0.9559
    },
    {
      "sent": "Other legislative, regulatory or industry measures related to the public health crisis involving the abuse of prescription opioid pain medication and the distribution of these medications could affect our business in ways that we may not be able to predict.",
      "score": -0.9118
    }
  ],
  "forward_snippets": [
    "Many forward-looking statements appear in MD&A and Risk Factors, but there are others throughout this report, which may be identified by words such as \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201clikely,\u201d and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals.",
    "Many forward-looking statements appear in MD&A and Risk Factors, but there are others throughout this report, which may be identified by words such as \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201clikely,\u201d and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals.",
    "Many forward-looking statements appear in MD&A and Risk Factors, but there are others throughout this report, which may be identified by words such as \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201clikely,\u201d and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals.",
    "Many forward-looking statements appear in MD&A and Risk Factors, but there are others throughout this report, which may be identified by words such as \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201clikely,\u201d and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals.",
    "See \"Critical Accounting Policies and Sensitive 4 Cardinal Health | Fiscal 2023 Form 10-K MD&A Overview Accounting Estimates\" section of this MD&A, and Note 4 and Note 8 of the \"Notes \nguidance, statements of outlook and expense accruals."
  ]
}